Marc Tessier-lavigne - Net Worth and Insider Trading

Marc Tessier-lavigne Net Worth

The estimated net worth of Marc Tessier-lavigne is at least $74 Million dollars as of 2024-11-13. Marc Tessier-lavigne is the Director of Denali Therapeutics Inc and owns about 2,107,225 shares of Denali Therapeutics Inc (DNLI) stock worth over $63 Million. Marc Tessier-lavigne is the Director of Juno Therapeutics Inc and owns about 75,000 shares of Juno Therapeutics Inc (JUNO) stock worth over $7 Million. Marc Tessier-lavigne is also the Director of Agios Pharmaceuticals Inc and owns about 45,454 shares of Agios Pharmaceuticals Inc (AGIO) stock worth over $3 Million. Besides these, Marc Tessier-lavigne also holds Regeneron Pharmaceuticals Inc (REGN) . Details can be seen in Marc Tessier-lavigne's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Marc Tessier-lavigne has not made any transactions after 2022-11-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Marc Tessier-lavigne

To

Marc Tessier-lavigne Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Marc Tessier-lavigne owns 5 companies in total, including Denali Therapeutics Inc (DNLI) , Regeneron Pharmaceuticals Inc (REGN) , and Agios Pharmaceuticals Inc (AGIO) among others .

Click here to see the complete history of Marc Tessier-lavigne’s form 4 insider trades.

Insider Ownership Summary of Marc Tessier-lavigne

Ticker Comapny Transaction Date Type of Owner
DNLI Denali Therapeutics Inc 2022-11-23 director
REGN Regeneron Pharmaceuticals Inc 2022-10-03 director
AGIO Agios Pharmaceuticals Inc 2013-07-23 director
LIMIT LIMIT 2016-06-17 director
LIMIT LIMIT 2011-12-12 director

Marc Tessier-lavigne Latest Holdings Summary

Marc Tessier-lavigne currently owns a total of 4 stocks. Among these stocks, Marc Tessier-lavigne owns 2,107,225 shares of Denali Therapeutics Inc (DNLI) as of November 23, 2022, with a value of $63 Million and a weighting of 85.06%. Marc Tessier-lavigne owns 75,000 shares of Juno Therapeutics Inc (JUNO) as of December 18, 2014, with a value of $7 Million and a weighting of 8.8%. Marc Tessier-lavigne also owns 45,454 shares of Agios Pharmaceuticals Inc (AGIO) as of July 23, 2013, with a value of $3 Million and a weighting of 3.62%. The other 1 stocks Regeneron Pharmaceuticals Inc (REGN) have a combined weighting of 2.51% among all his current holdings.

Latest Holdings of Marc Tessier-lavigne

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
DNLI Denali Therapeutics Inc 2022-11-23 2,107,225 29.90 63,006,028
JUNO Juno Therapeutics Inc 2014-12-18 75,000 86.96 6,522,000
AGIO Agios Pharmaceuticals Inc 2013-07-23 45,454 59.02 2,682,695
REGN Regeneron Pharmaceuticals Inc 2022-10-03 2,269 821.00 1,862,849

Holding Weightings of Marc Tessier-lavigne


Marc Tessier-lavigne Form 4 Trading Tracker

According to the SEC Form 4 filings, Marc Tessier-lavigne has made a total of 11 transactions in Denali Therapeutics Inc (DNLI) over the past 5 years, including 0 buys and 11 sells. The most-recent trade in Denali Therapeutics Inc is the sale of 20,000 shares on November 23, 2022, which brought Marc Tessier-lavigne around $609,600.

According to the SEC Form 4 filings, Marc Tessier-lavigne has made a total of 0 transactions in Juno Therapeutics Inc (JUNO) over the past 5 years. The most-recent trade in Juno Therapeutics Inc is the sale of 0 shares on December 18, 2014, which brought Marc Tessier-lavigne around $0.

According to the SEC Form 4 filings, Marc Tessier-lavigne has made a total of 0 transactions in Agios Pharmaceuticals Inc (AGIO) over the past 5 years. The most-recent trade in Agios Pharmaceuticals Inc is the sale of 0 shares on July 23, 2013, which brought Marc Tessier-lavigne around $0.

More details on Marc Tessier-lavigne's insider transactions can be found in the Insider Trading History of Marc Tessier-lavigne table.

Insider Trading History of Marc Tessier-lavigne

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Marc Tessier-lavigne Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Marc Tessier-lavigne Ownership Network

Ownership Network List of Marc Tessier-lavigne

No Data

Ownership Network Relation of Marc Tessier-lavigne

Insider Network Chart

Marc Tessier-lavigne Owned Company Details

What does Denali Therapeutics Inc do?

Who are the key executives at Denali Therapeutics Inc?

Marc Tessier-lavigne is the director of Denali Therapeutics Inc. Other key executives at Denali Therapeutics Inc include COO and Secretary Alexander O. Schuth , director & President and CEO Ryan J. Watts , and CFO and Treasurer Steve E. Krognes .

Denali Therapeutics Inc (DNLI) Insider Trades Summary

Over the past 18 months, Marc Tessier-lavigne made no insider transaction in Denali Therapeutics Inc (DNLI). Other recent insider transactions involving Denali Therapeutics Inc (DNLI) include a net sale of 29,606 shares made by Vicki L Sato , a net sale of 99,326 shares made by Alexander O. Schuth , and a net sale of 54,249 shares made by Carole Ho .

In summary, during the past 3 months, insiders sold 128,556 shares of Denali Therapeutics Inc (DNLI) in total and bought 0 shares, with a net sale of 128,556 shares. During the past 18 months, 478,916 shares of Denali Therapeutics Inc (DNLI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 478,916 shares.

Denali Therapeutics Inc (DNLI)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Denali Therapeutics Inc Insider Transactions

No Available Data

Marc Tessier-lavigne Mailing Address

Above is the net worth, insider trading, and ownership report for Marc Tessier-lavigne. You might contact Marc Tessier-lavigne via mailing address: 1 Dna Way, South San Francisco Ca 94080.